Lomitapide (Juxtapid) is a microsomal triglyceride transfer protein (MTP) inhibitor, primarily indicated for the treatment of homozygous familial hypercholesterolemia (HoFH). Although this medication demonstrates significant efficacy in lowering blood lipids, special attention must be paid to its potential side effects and medication precautions during use.

Side Effects of Lomitapide (Juxtapid)

Gastrointestinal Adverse Reactions

Diarrhea: Incidence rate of 79%, with 14% of patients experiencing severe diarrhea.

Nausea: Incidence rate of 65%.

Dyspepsia: Incidence rate of 38%.

Vomiting: Incidence rate of 34%, with 10% of cases being severe vomiting.

Abdominal pain: Incidence rate of 34%.

Adverse Reactions in Other Systems

Weight loss: Incidence rate of 24%.

Fatigue: Incidence rate of 17%.

Back pain: Incidence rate of 14%.

Headache: Incidence rate of 14%.

Dizziness: Incidence rate of 10%.

Severe Side Effects of Lomitapide (Juxtapid)

Transaminase Elevation

34% of patients (10 out of 29) experienced at least one episode of ALT or AST elevation ≥3 times the upper limit of normal (ULN).

14% of patients had ALT or AST elevation ≥5 times the ULN.

3% of patients had ALT elevation ≥10 times the ULN.

Hepatic Steatosis

After 26 weeks and 78 weeks of treatment, the median absolute increase in liver fat was 6% in both periods.

78% of patients had an increase in liver fat >5%.

13% of patients had an increase in liver fat >20%.

Severe Gastrointestinal Reactions

21% of patients reported severe gastrointestinal reactions.

14% of patients discontinued treatment early due to gastrointestinal reactions.

Medication Precautions for Lomitapide (Juxtapid)

Liver Function Monitoring Protocol

Pre-treatment monitoring: Measure ALT, AST, alkaline phosphatase, and total bilirubin.

Monitoring during treatment:

First year: Conduct liver-related tests before each dose increase or monthly, whichever comes first.

After one year: Conduct tests at least every 3 months.

Medication Restrictions for Specific Populations

Patients with renal impairment: End-stage renal disease patients receiving dialysis should not exceed a daily dose of 40mg.

Patients with hepatic impairment: Patients with mild hepatic impairment should not exceed a daily dose of 40mg; patients with moderate or severe hepatic impairment are contraindicated.

Medications Requiring Dosage Adjustment

Weak CYP3A4 inhibitors: The dose of lomitapide must not exceed 30mg per day.

Warfarin: Regular monitoring of INR values is required.

Simvastatin: When initiating JUXTAPID, the dose of simvastatin should be reduced by 50%.